Adial Pharmaceuticals (ADIL) Expected to Announce Earnings on Wednesday

Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) is anticipated to post its Q3 2026 results on Wednesday, November 18th. Analysts expect the company to announce earnings of ($0.1750) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 7:00 AM ET.

Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($11.25) EPS for the quarter, missing the consensus estimate of ($1.03) by ($10.22).

Adial Pharmaceuticals Stock Down 3.4%

NASDAQ:ADIL opened at $4.88 on Tuesday. Adial Pharmaceuticals has a twelve month low of $1.31 and a twelve month high of $9.30. The business has a 50 day moving average price of $4.45 and a two-hundred day moving average price of $3.23. The company has a market cap of $12.80 million, a P/E ratio of -0.33 and a beta of 1.50.

Analyst Ratings Changes

A number of research firms have commented on ADIL. Weiss Ratings raised shares of Adial Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, October 28th. Alliance Global Partners started coverage on shares of Adial Pharmaceuticals in a report on Monday, August 3rd. They set a “buy” rating and a $11.00 price target for the company. Finally, Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, August 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Adial Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $8.33.

Get Our Latest Stock Analysis on ADIL

About Adial Pharmaceuticals

(Get Free Report)

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders, particularly alcohol use disorder. Its lead candidate, AD04, is a formulation of ondansetron being studied as a potential treatment for people with alcohol use disorder who have certain genetic markers. The company’s approach combines drug development with pharmacogenetic testing to identify patients who may be more likely to benefit from treatment. AD04 remains investigational and is not an approved therapy.

See Also

Earnings History for Adial Pharmaceuticals (NASDAQ:ADIL)

Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.